Funding profile · Research infrastructure

Adaptyv Bio

About $50.5 million announced across three rounds since 2022, and one SEC filing to show for it: a 2021 crowdfunding notice with a $107,000 ceiling. The lab itself is a wholly owned Swiss subsidiary of a Delaware parent.

$50.5MTotal across three announced rounds, 2022 to 2026
$40.0MSeries A, August 2026, led by Highland Europe
$8.0MSeed led by ACE Ventures
$107KCeiling on the only SEC registered offering, a 2021 Reg CF SAFE

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Aug 2021 Y Combinator batch plus Swiss grants $125,000 plus CHF 140,000 Y Combinator; EPFL Ignition; FIT Innogrant Independent
Nov 2021 to Apr 2022 Regulation Crowdfunding offering of SAFEs $50,000 target, $107,000 cap Wefunder investors through an LLC series Form C
Feb 2022 Pre seed About $2.5M Wingman Ventures (lead), Acequia Capital, Hawktail, Rheingau Founders, Founders Inc, Axial, Venture Kick, S2S Ventures, Y Combinator Independent
Late 2024 or 2025 Seed $8.0M ACE Ventures (lead), ByFounders, Founderful, LongGame, angels Company and press
Aug 2026 Series A $40.0M, also reported as €34.35M and $25.9M Highland Europe (lead), ACE Ventures, ByFounders, Y Combinator Figures disagree

What the filings show

Adaptyv Biosystems Inc · Form C · filed Nov 22, 2021

Issuer
Delaware corporation, incorporated Jul 14, 2021
Security
SAFE, $1.00 per interest
Offered
$50,000 target · $107,000 maximum · deadline Apr 30, 2022
Co-issuer
Adaptyv Biosystems I, a series of Wefunder SPV, LLC
Portal
Wefunder Portal LLC, paid 3.5% on a successful raise
Financials
Total assets $943,636, all cash · revenue $0 · net loss $99,531 · 4 employees
Signatories
Julian Englert (CEO); Amir Shahein (CSO); Moustafa Houmani (CTO); Daniel Nakhaee-Zadeh Gutierrez (COO)
Filing
SEC EDGAR, CIK 0001894760

Adaptyv Biosystems Sàrl · Vaud commercial register · entered Nov 22, 2021

Seat
Route de la Corniche 5, Starlab, 1066 Epalinges
Purpose
A protein engineering platform using synthetic biology and nanofluidics
Share capital
CHF 20,000, in 200 shares of CHF 100
Sole member
Adaptyv Biosystems, Inc., Wilmington, holding all 200 shares
Managers
Julian Englert, president; Daniel Nakhaee-Zadeh Gutierrez
Audit
Opted out of a limited audit, Nov 4, 2021
Filing
UID CHE-364.352.615

Reading the filings

  1. No Form D exists.About $50.5 million has been announced and none of it appears on a Regulation D notice. The only EDGAR filing is the 2021 crowdfunding statement. That fits a Delaware issuer selling mostly to European funds outside Regulation D, and it means the usual American paper trail of offering size, investor counts and related persons stops in 2021.
  2. The crowdfunding round was a rounding error.The $107,000 cap is about 4% of the $2.5 million pre seed announced on Feb 14, 2022, while the crowdfunding deadline of Apr 30, 2022 was still running. That is a community allocation, not a source of funds.
  3. The 2021 balance sheet is larger than the named capital.The filing reports $943,636 in assets, all cash, against $0 revenue and a $99,531 loss. The publicly named early money was $125,000 from Y Combinator and CHF 140,000 in Swiss grants, roughly $275,000. The rest came from somewhere the filing does not name, and the pre seed was not announced for another three months.
  4. The lab is a subsidiary, the equity is in Delaware.The Swiss operating entity carries CHF 20,000 of capital and one member, the Delaware parent. The register is the only filed record tracking the operating business, and it shows no capital increase since 2021.
  5. The Series A figure depends on the outlet.Most reports say $40 million. EU-Startups converts it to €34.35 million. Dealroom runs a $40M headline over a body that says US$25.9M. No filing settles it.
  6. The seed date does not settle either.EU-Startups says ACE led the seed in November 2024. The company’s own September 2025 post says it raised the $8 million round earlier that same year. A round closed in late 2024 and announced ten months later is ordinary, but it is a different capital position during the competitions.

Commercial signals

Signal Detail Source type
Pricing Published configurator: from $99 per protein, with a 60 protein two target job quoted at $169 per sequence and $10,140 total. Turnaround given as 3 to 4 weeks on the service page. Company-stated
Customers More than 30 in 2025, more than 100 by August 2026, with Roche, Novo Nordisk, Chai Discovery and Boltz named. No contract terms published. Company-stated
Throughput Reported up more than fivefold in the year to August 2026, with a plan to triple capacity again by the end of 2026. Company-stated
Revenue Said to be up roughly tenfold since the seed. No figure disclosed, and neither entity files public accounts. Company-stated
Headcount 4 at the 2021 SEC filing, 12 in the April 2023 launch release, 9 at the seed per the lead investor, about 25 at the Series A with a target of about 60. Record and company
Regulatory No FDA record, no registered trial, no NIH or NSF award. A tools and services business, not a product company. Not found

What to watch

  • A first Form D, due within 15 days of any US sale made under Regulation D, which would name investors, amounts and related persons.
  • Anything that settles the $40 million, €34.35 million and $25.9 million versions of the Series A.
  • A UK entity on Companies House for the London lab announced for the fourth quarter of 2026.
  • Changes in the Vaud register: a capital increase, new managers, or a change of sole member.
  • A first disclosed revenue figure, or a named multi year contract with a pharma customer.

The Adaptyv Bio story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • PipeBio: Shared investor: Acequia Capital. A five person Danish company that built cloud bioinformatics for antibody discovery, got its name into the methods sections of twenty published papers, and was bought by
  • Forcyte Biotechnologies: Shared investor: Acequia Capital. A UCLA spinout that turned how hard a single cell squeezes into a number, then ran that number as a drug screen
  • Zeit Medical: Shared investor: Acequia Capital. A soft EEG headband built to notice a stroke while its wearer is asleep and raise the alarm before anyone else can
  • SFA Therapeutics: Shared investor: Acequia Capital. A Temple University spinout turning short chain fatty acids from the human gut into oral pills

Sources

  1. Public recordForm C, Adaptyv Biosystems Inc, CIK 0001894760SEC EDGAR · Nov 22, 2021
  2. Public recordEDGAR search, no Form D on fileSEC · checked Sep 22, 2026
  3. Public recordCommercial register entry, Adaptyv Biosystems SàrlVaud · Nov 22, 2021
  4. IndependentEPFL spin-off secures funding from Y CombinatorStartupticker.ch · Aug 4, 2021
  5. IndependentAdaptyv Biosystems raises USD 2.5 millionVenture Kick · Feb 14, 2022
  6. IndependentAdaptyv raises USD 8 millionGGBa · Oct 27, 2025
  7. IndependentLausanne-based Adaptyv raises €34.35 million Series AEU-Startups · Aug 27, 2026
  8. IndependentAdaptyv raises $40M Series ADealroom · Aug 26, 2026
  9. IndependentAdaptyv Raises $40 Million Series APulse 2.0 · Aug 27, 2026
  10. InvestorACE Ventures leads $8 million seed round in Adaptyv BioACE Ventures · 2025
  11. CompanyAdaptyv is the cloud lab for protein designersAdaptyv Bio · Sep 2025
  12. CompanyBinding service page and pricing configuratoradaptyvbio.com · accessed Sep 22, 2026

Compiled from SEC and Swiss commercial register records and published reports as of September 22, 2026. Adaptyv has no Form D on file; Regulation Crowdfunding notices report a target and a maximum, not an amount raised. Healthcare Venture Capital Fund holds no position in Adaptyv Bio. This page is not an offer to sell or a recommendation to buy any security.